← Back to overview

VRTX Vertex Pharmaceuticals Incorpor

Biotechnology · $477.36 +0.90%
EN PL
Price Alert:

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
55.5
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
455.74 / 407.86 / 196.15
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
16.76 / 17.16
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
28.3
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
121.16B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
362.50 – 533.67
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

Vertex Pharmaceuticals Incorpor is trading at $477.36, +0.90% versus the previous close. The price sits roughly in the middle of its 52-week range.
RSI is in a neutral range — no strong overbought/oversold signal.
The 50-day average is above the 200-day average ("golden cross" territory) — a commonly watched bullish signal.
MACD is below its signal line — momentum currently leans negative.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

Vortex Energy Corp. Announces Marketing Program
GlobeNewswire · 2026-07-24 21:00
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?
Trefis · 2026-07-23 15:00
3 Healthcare Stocks with Competitive Advantages
StockStory · 2026-07-23 10:22
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Zacks · 2026-07-22 21:50
Vertex was sole bidder in high-premium Crinetics acquisition
BioPharma Dive · 2026-07-22 16:48
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
CNW Group · 2026-07-21 13:00
Biotech IPO Gains Crush AI Listings With Standout 55% Return
Bloomberg · 2026-07-21 12:35
Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19
MT Newswires · 2026-07-21 09:30
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.